anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An article for the sustained release of an insecticide into the ambient air comprises an elastomeric matrix, with the insecticide dissolved in the matrix. The matrix material has a modulus between about 104 Pa and about 108 Pa at 23 DEG  C., and a glass transition temperature less than 0 DEG  C. The matrix comprises polyurethane formed by reacting hydroxyl-terminated polybutadiene or polyisoprene and 4,4' diphenylmethane diisocyanate, and the insecticide is 2,2' dichlorovinyl dimethyl phosphate. The insecticide-containing matrix is contained in a plastic bottle, and typically protected against inadvertent skin contact by means of a dermal barrier. The article also comprises means for activating the article such that, prior to activation, release of insecticide into the ambient air is prevented, whereas such release can take place after activation. Exemplary activation means comprise a metal foil seal of the plastic bottle. The article is effective in controlling insect infestation (e.g., ants, fire ants, bees, wasps, cockroaches) in enclosures, e.g., enclosures of the type used to protect outdoor utility equipment.
Pseudogout is characterized by the deposition of calcium pyrophosphate dihydrate crystals (CPPD), primarily affecting large joints. Extra-articular manifestations, particularly in the head and neck region, are exceedingly rare. We report a unique case of bilateral isolated pseudogout of the middle ear manifesting with progressive conductive hearing loss as the first and only symptom of pseudogout. Otoscopy and CT scan often yield a differential diagnosis that includes tumors or cholesteatoma, necessitating surgery with histopathological examination. The definitive diagnosis is confirmed upon identification of calcium pyrophosphate dihydrate crystals. In most cases, removal of the crystals results in resolution of conductive hearing loss. Laryngoscope, 134:5131-5134, 2024.
PROBLEM TO BE SOLVED: To provide the subject new antibody capable of specifically recognizing a specific amino acid sequence in a capsid antigen protein molecule of feline immunodeficiency virus(FIV), detecting FIV gag antigen and useful e.g. for the diagnosis of the FIV infection of an animal of the family Felidae. SOLUTION: This new monoclonal antibody specifically recognizes the amino acid sequence corresponding to the amino acid numbers of 4-12 in the amino acid sequence expressed by the formula in the molecule of a capsid antigen protein (FIV capsid antigen) of feline immunodeficiency virus. It is effective for detecting FIV gag antigen and is useful e.g. for the diagnosis of the FIV infection of an animal of the family Felidae. The monoclonal antibody can be produced by immunizing a BALB/c mouse with a recombinant FIV capsid antigen in combination with an adjuvant, collecting the spleen cell after the final immunization, fusing with a myeloma cell, cloning the fused cell by the selective culture in HAT medium, cloning the obtained hybridoma by limiting dilution analysis and finally culturing the cloned product.
<P>PROBLEM TO BE SOLVED: To purify bacterial capsular polysaccharides related to vaccines, especially vaccines for meningococcal infections and meningococcal diseases.  <P>SOLUTION: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using an alcohol as a solvent. The present invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of the polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides originated from the serogroups A and C, the present invention provides a vaccine that the ratio (w/w) of MenA saccharide to MenC saccharide is >1.  <P>COPYRIGHT: (C)2009,JPO&INPIT
OBJECTIVES: To review the efficacy of nebulised magnesium sulfate (MgSO4) in acute asthma in children.
METHODS: The authors searched Medline, Embase, Web of Science and Cochrane Library for randomised controlled trials (RCTs) published until 15 December 2023. RCTs were included if they compared the efficacy and safety of nebulised MgSO4 as a second-line agent in children presenting with acute asthma exacerbation. A random-effects meta-analysis was performed, and the Risk of Bias V.2 tool was used to assess the biases among them.
RESULTS: 10 RCTs enrolling 2301 children with acute asthma were included. All trials were placebo controlled and administered nebulised MgSO4/placebo and salbutamol (±ipratropium bromide). There was no significant difference in Composite Asthma Severity Score between the two groups (6 RCTs, 1953 participants; standardised mean difference: -0.09; 95% CI: -0.2 to +0.02, I2=21%). Children in the MgSO4 group have significantly better peak expiratory flow rate (% predicted) than the control group (2 RCTs, 145 participants; mean difference: 19.3; 95% CI: 8.9 to 29.8; I2=0%). There was no difference in the need for hospitalisation, intensive care unit admission or duration of hospital stay. Adverse events were minor, infrequent (7.3%) and similar among the two groups.
CONCLUSIONS: There is low-certainty evidence that nebulised MgSO4 as an add-on second-line therapy for acute asthma in children does not reduce asthma severity or a need for hospitalisation. However, it was associated with slightly better lung functions. The current evidence does not support the routine use of nebulised MgSO4 in paediatric acute asthma management.
PROSPERO REGISTRATION NUMBER: CRD42022373692.
Participants will receive a weight-based initial (loading) dose of ALXN1720 on Day 1, followed by weight-based maintenance treatment with ALXN1720 on Day 8 and once every week (Q1W) thereafter for a total of 26 weeks. Following this randomized controlled treatment (RCT) period, all participants will receive ALXN1720 in an open-label extension (OLE) period of 105 weeks.
INTRODUCTION: Post-reflux swallow-induced peristaltic wave index (PSPWI) and mean nocturnal baseline impedance (MNBI) are novel parameters reflect esophageal clearance capacity and mucosal integrity. They hold potential in aiding the recognition of gastroesophageal reflux-induced chronic cough (GERC). Our study aims to investigate their diagnostic value in GERC.
METHODS: This study included patients suspected GERC. General information and relevant laboratory examinations were collected, and final diagnosis were determined following guidelines for chronic cough. The parameters of multichannel intraluminal impedance-pH monitoring (MII-pH) in patients were analyzed and compared to explore their diagnostic value in GERC.
RESULTS: A total of 186 patients were enrolled in this study. The diagnostic value of PSPWI for GERC was significant, with the area under the working curve (AUC) of 0.757 and a cutoff value of 39.4%, which was not statistically different from that of acid exposure time (AET) (p > 0.05). The combined diagnostic value of AET > 4.4% and PSPWI < 39.4% was superior to using AET > 4.4% alone (p < 0.05). Additionally, MNBI and distal MNBI also contributed to the diagnosis of GERC, with AUC values of 0.639 and 0.624, respectively. AET > 4.4% or PSPWI < 39.4% is associated with a 44% reduction in missed diagnoses of non-acid GERC compared to AET > 6.0% or symptom association probability (SAP) ≥ 95%, and may be more favorable for identifying GERC.
CONCLUSION: The diagnostic value of PSPWI for GERC is comparable to that of AET. Combining PSPWI < 39.4% or AET > 4.4% can improve the diagnostic efficiency by reducing the risk of missed diagnoses in cases where non-acid reflux is predominant. Distal MNBI and MNBI can serve as secondary reference indices in the diagnosis of GERC.
Careful observation is required when amantadine hydrochloride is administered concurrently with central nervous system stimulants. Agents with anticholinergic properties may potentiate the anticholinergic-like side effects of amantadine.

Coadministration of thioridazine has been reported to worsen the tremor in elderly patients with Parkinson’s disease, however, it is not known if other phenothiazines produce a similar response.

Coadministration of Dyazide (triamterene/hydrochlorothiazide) resulted in a higher plasma amantadine concentration in a 61-year-old man receiving amantadine (hydrochloride capsules) 100 mg t.i.d. for Parkinson’s disease.1 It is not known which of the components of Dyazide contributed to the observation or if related drugs produce a similar response.

Coadministration of quinine or quinidine with amantadine was shown to reduce the renal clearance of amantadine by about 30%.

The concurrent use of amantadine hydrochloride with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of the potential for interference between these products, LAIV should not be administered within 2 weeks before or 48 hours after administration of amantadine hydrochloride, unless medically indicated. The concern about possible interference arises from the potential for antiviral drugs to inhibit replication of live vaccine virus. Trivalent inactivated influenza vaccine can be administered at any time relative to use of amantadine hydrochloride.
It is crucial to maintain the anatomic condyle positions during orthognathic surgery to prevent iatrogenic temporomandibular joint complications. Condyle shunts are affected directly under general anesthesia because of the joint and muscle relaxation. Surgical guidance appliances are prepared according to the TMJ records taken chairside while patients are in an upright position. During surgery, these appliances are applied in a supine position while the muscles are relaxed. Postoperative and long-term effects of TMJ and muscle relaxation obtained under general anesthesia in class III and asymmetric patients will be examined. Patients who had occlusal splint before records taken will be evaluated in terms of condyle location by MPI.

Our aim is to evaluate whether the use of MR Splint has a statistically significant effect on muscle relaxation-induced condyle position deviations under general anesthesia in Class III Laterognathia patients.
BACKGROUND: Patients with lung adenocarcinoma (LUAD) generally have poor prognosis. The role of striatin-interacting protein 2 (STRIP2) in LUAD remain unclear.
METHODS: Liquid chromatography-mass spectrometry analyses were used to screen the STRIP2-binding proteins and co-immunoprecipitation verified these interactions. A dual luciferase reporter assay explored the transcription factor activating STRIP2 transcription. Xenograft and lung metastasis models assessed STRIP2's role in tumor growth and metastasis in vivo.
RESULTS: STRIP2 is highly expressed in LUAD tissues and is linked to poor prognosis. STRIP2 expression in LUAD cells significantly promoted cell proliferation, invasion, and migration in vitro and in vivo. Mechanistically, STRIP2 boosted the PI3K/AKT/mTOR/MYC cascades by binding AKT. In addition, specificity protein 1, potently activated STRIP2 transcription by binding to the STRIP2 promoter. Blocking STRIP2 reduces tumor growth and lung metastasis in xenograft models.
CONCLUSIONS: Our study identifies STRIP2 is a key driver of LUAD progression and a potential therapeutic target.
Thrombin is now known to mediate a number of potent biological effects on cells bearing high-affinity thrombin receptors. These effects depend, at least in part, upon receptor occupancy signals generated by thrombin's interaction with the high affinity thrombin receptor. The present inventors have formulated synthetic thrombin derivatives capable of selectively stimulating or inhibiting thrombin receptor occupancy signals. The stimulatory thrombin derivatives to bind to cell surface thrombin receptors and stimulate DNA synthesis in cells treated with non-mitogenic concentrations of alpha-thrombin or phorbol myristate acetate. Thus, these peptides, which have both a thrombin receptor binding domain and a segment of amino acids with a sequence common to a number of serine proteases, appear to generate receptor-occupancy dependent mitogenic signals. The inhibitory derivatives, which have no serine esterase conserved amino acid sequences bind to thrombin receptors without generating receptor-occupancy dependent mitogenic signals. This invention describes the peptides and methods for using them to promote cell growth and wound healing or to inhibit scar formation, tissue adhesions, and tumor metastasis and angiogenesis.
A 75-year-old man underwent chemoradiotherapy for advanced esophageal cancer. After nine years, he was hospitalized for left pyothorax. Consequently, the patient underwent drainage and window opening surgery. He experienced cardiopulmonary arrest but was resuscitated. Based on cardiac catheterization data, the patient was diagnosed with constrictive pericarditis. Unfortunately, extracorporeal circulation did not improve his condition, and he ultimately died. An autopsy revealed adhesion between the pericardium and pleura, especially the pericardium in contact with the left thoracic cavity, which was markedly thickened. This suggests that constrictive pericarditis, a latent complication of chemoradiotherapy, is aggravated by pyothorax.
Provided herein is a composition comprising the following components: 0.1 -15 wt. -% of piroctone olamine, 17.5 -28 wt. -% of surfactant, 15 -35 wt. -% of alcohol solvent, and 0.1 -2 wt. -% of fatty acid ester or oil, wherein the weight percentage of each component is based on the total weight of the composition. And provided is a method for preparing the composition and relates to uses of the composition in personal or home care products.
FIELD: biotechnology. SUBSTANCE: biologically active substance has the natural and/or synthesized active components on the basis of bioactive components, filling agents or involuntary components. Bioactive components are collalytin and/or its components at weight content c1 and c2, respectively, and taken at the following limits:  . Content of filling agents, accessory and random or involuntary components in the substance is homogenized to a value determined by ratio of the weight ratio c4 of nonhomogeneous residue to the weight content c5 of the completely homogenized components at the limits: 1 ≤ (c4+c5)/c5 ≤ 10 5 . Ratio of minimal t1 and maximal t2 of hardness values distributed over the total surface of the substance provides at the limits: 1 ≤ (т1+αт2)/т2 ≤ 4 where α - an experimental coefficient at the limits: 0,4 ≤ α ≤ 3 and taken depending on the volume structure of substance and conditions of its final treatment. Biologically active substance is obtained by isolation of the preparation exhibiting collagenolytic activity from biological objects of marine origin or their elements in the presence of accessory additions. Biologically active components are separated from that to be used, purified and dried. Process of preparing the raw materials and the method of the substance preparing are optimized. EFFECT: improved method of preparing, broadened functional possibilities of the biologically active substance using, enhanced effectiveness of the substance consumption use in practice. 4 cl, 1 ex
Patients undergo bronchoscopy over 30-60 minutes and receive canakinumab SC 60 minutes and 2 weeks after the initial bronchoscopy. Patients undergo an additional bronchoscopy on day 77. Patients undergo buccal, nasal, and blood sample collection and CO testing on study.
Lidocaine patch 5% has not been studied in labor and delivery. Lidocaine is not contraindicated in labor and delivery. Should lidocaine patch 5% be used concomitantly with other products containing lidocaine, total doses contributed by all formulations must be considered.

Lidocaine patch 5% has not been studied in nursing mothers. Lidocaine is excreted in human milk, and the milk:plasma ratio of lidocaine is 0.4. Caution should be exercised when lidocaine patch 5% is administered to a nursing woman.
Patients with depression and cardiovascular comorbidities have a worse prognosis, a sharply reduced quality of life, and a much higher incidence of fatal CVD events, such as acute infarction, than patients with a single disease. However, due to the variety of potential causative factors and clinical manifestations, population variability, long duration of the disease, as well as neurological disorders of the exact causative mechanism still unclear, the psychological assessment among patients with cardiovascular diseases is remarkably inadequate studied.

In this study, two cohorts are established that include 2000 hospitalized patients and 5000 of the entire population. All individuals are screened for depression and anxiety. Those who score positive will be advised to enroll in this study. Patients are then randomized to receive collaborative care involving the patient, the patient's primary care physician, cardiologist and nurse case manager, or usual care is defined for each patient. Whole blood and serum samples are obtained from all patients, which will be measured for a panel of metabolic and inflammatory indicators. Patients in both cohorts will be monitored for depression severity and duration at 6 and 12 months after enrollment. A statistical technique is applied to determine the effect size of potential risk factors.
A method for inhibiting apoptosis of a cell expressing a death receptor of the TNFR family is disclosed. The method involves treating the cell with a Receptor Internalization and Degradation (RID) protein complex containing RIDα (10.4K) and RIDβ (14.5K) proteins encoded by the E3 region of adenovirus. The cell can be treated by administering to the cell a polynucleotide expressing the RID complex or by administering to the cell a composition containing the RID complex. Compositions containing a RID complex are also disclosed. The compositions and method are useful in the treatment of cancer, degenerative and immune disorders, as well as in promoting survival of tissue transplants. An adenovirus vector for delivering the RID complex to cells is also disclosed.
Participants receive envafolimab 150 mg subcutaneously (SC) on Day 1 of each week cycle (QW) for 8 cycles followed by envafolimab 300 mg SC on Day 1 of each 3-week cycle (Q3W) until disease progression, intolerable toxicity, investigator determines that the participant cannot continue to benefit, withdraws informed consent, or envafolimab treatment over 2 years. During the QW dosing period of envafolimab, participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 45 Gray Units (Gy)with the total duration of radiation treatment not to exceed 56 days.
The invention relates to a polypeptide carrier for delivering nucleic acid medicines, and the amino acid composition of the polypeptide carrier is shown as SEQ ID NO. 3. The invention also provides application of the polypeptide carrier, a corresponding nucleic acid medicament for treating tumors and a preparation method thereof. The MMP2 enzyme response peptide designed by the invention can be effectively combined with miRNAmics, and RBCM endows nano particles with stealth function, so that the cycle life, immune escape and biosafety are improved. When MMP2 exists in a large amount in lung cancer cells after the bionic nano-particles responded by MMP2 enzyme are absorbed by the lung cancer cells, miR-126-3p micrometers are released, and apoptosis of the cancer cells is effectively induced. The nucleic acid medicine for treating tumors disclosed by the invention provides a novel strategy for treating lung cancer with great application prospect.
Participants in the wait-list group will be advised to continue their habitual physical activity next to usual medical care. A yoga or aerobic exercise program of 8 weeks will be offered after the ending of the study period.
PURPOSE:To provide an antiandrogen agent containing 1,4,6-trihydroxyxanthone as an active component, free from steroid-type nucleus and having high safety in use. CONSTITUTION:The objective agent can be produced by using 1,4,6- trihydroxyxanthone as an active compound and forming to a drug form by conventional method. It can be used in the form of tablet, powder, fine particle, granule, capsule, syrup, suppository or external drug. The dose for adult is 0.002-10mg/day for oral drug and 0.005-25mg/day for suppository in 1-4 divided doses. In the case of external drug, a preparation containing 0.00001-0.1wt.% of the active component is applied several time a day according to the symptom. It is useful for the remedy of androgen-dependent diseases such as hirsutism, acne, male baldness, prostatic hypertrophy, prostatic tumor and precocious puberty of boy.
It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.
A computer-implemented method of determining a cause of a trend in vital sign data of a subject comprises obtaining vital signs data of a subject, determining a trend in the vital sign data over time and determining a most likely cause of the trend in the vital sign data in dependence on one or more stored weights each associated with one or more possible causes. Each stored weight is indicative of a likelihood of the associated cause being responsible for the trend in the vital signs data. The one or more causes may include a medication event in which the subject has taken a specified medication, and/or includes a missed medication event. The vital sign data may be obtained from a wearable electronic device. The device may output an alert for example by sending a text message or email. A computer-implemented method of generating the stored weights based on vital sign data for a plurality of individuals is also disclosed.
Systems and methods as disclosed herein are provided for generating a research study application. A request to generate a research study is received from a user. A plurality of task generation options are presented on a graphical user interface of an electronic device. The plurality of task generation options are selected from the group consisting of a consent survey, an eligibility survey, a medical history survey, and a medical tracking survey. Input regarding the plurality of task generation options is received from the user. Additionally, a research study application is generated based on information received from the user.
During our study period, transplants with a planned recipient anesthesia starting time between 10:00pm-6:00am will be allowed to move to a 6:00-8:00am start at the earliest. To be eligible, donor lungs cross clamp time have to occur between 6pm and 4am and lungs need to be suitable for transplantation without the need for ex vivo lung evaluation. Lungs meeting criteria for direct transplantation will be transported in the usual fashion in a cooler of ice at 4oC and upon arrival to Shands UF Health they will immediately be transferred to cold static preservation at 10oC within a specific refrigerator placed in the Shands UF Health OR. The maximum preservation time from donor cold flush (cross clamp) to recipient anesthesia start should be 12 hours and the recipient procedure should not start before 6am.